GlassScriptPhysician profile
Warren Steven Paroly
NPI 1306981527
$3,491.82
in general payments reported to CMS, 2019-2025
43 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $189 · 2021: $302 · 2022: $334 · 2023: $403 · 2024: $802 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $438.19 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $201.20 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.94 | 2019-2025 | Opdivo |
| Karyopharm Therapeutics INC. | $175.18 | 2021-2025 | Xpovio |
| Celgene Corporation | $162.97 | 2019-2024 | Reblozyl |
| Daiichi Sankyo INC. | $160.31 | 2021-2024 | Enhertu, Injectafer |
| Beigene USA, INC. | $159.86 | 2022-2024 | Brukinsa |
| Regeneron Pharmaceuticals, INC. | $149.00 | 2025 | Libtayo |
| Seagen INC. | $145.12 | 2019-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $132.67 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $118.41 | 2025 | |
| Coherus Oncology, INC. | $108.93 | 2022-2025 | Loqtorzi |
| Lilly USA, LLC | $104.92 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $89.60 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $86.36 | 2019-2023 |
Show all 41 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Paroly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.